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Abstract
In genetic association studies, rare variants with extremely small allele frequency play
a crucial role in complex traits, and the set-based testing methods that jointly assess
the effects of groups of single nucleotide polymorphisms (SNPs) were developed to
improve powers for the association tests. However, the powers of these tests are still
severely limited due to the extremely small allele frequency, and precise estimations
for the effect sizes of individual SNPs are substantially impossible. In this article, we
provide an efficient set-based inference framework that addresses the two important
issues simultaneously based on a Bayesian semiparametric multilevel mixture model.
We propose to use the multilevel hierarchical model that incorporate the variations in
set-specific effects and variant-specific effects, and to apply the optimal discovery pro-
cedure (ODP) that achieves the largest overall power in multiple significance testing.
In addition, we provide Bayesian optimal “set-based” estimator of the empirical dis-
tribution of effect sizes. Efficiency of the proposed methods is demonstrated through
application to a genome-wide association study of coronary artery disease (CAD),
and through simulation studies. These results suggested there could be a lot of rare
variants with large effect sizes for CAD, and the number of significant sets detected
by the ODP was much greater than those by existing methods.
Key words: empirical Bayes; genome wide association study; effect size estimation;
optimal discovery procedure
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1 Introduction
The advent of high-throughput technologies have realized the whole genome sequenc-
ing, and the genome-wide association studies (GWAS) have successfully identified
many common single nucleotide polymorphisms (SNPs) associated with complex
traits in the last two decades (Manolio et al., 2008). However, a large portion of
the heritability of diseases, behaviors, and other phenotypes cannot be accounted by
these genetic variations, and it is the well-known the “missing heritability” problem
(Cohen et al., 2004). To explain the missing heritability, recent studies have gradually
revealed that “rare variants” have highly impacts to the complex traits, which are the
minor allele frequency (MAF) are smaller than 1-5% in populations (e.g. Holm et al.,
2011; Rivas et al., 2011). Besides, detections of the associations of the rare variants
are challenging due to their extremely low frequency of rare variants and lacks of the
statistical powers for the conventional association tests.
To overcome this underpowered problem, set-based testing methods that jointly
assess the associations of a group of SNPs (e.g., a set on a gene, pathway, or network)
with a phenotype have been developed in the past decade (Wu et al., 2011; Lee
et al., 2014). Various set-based tests for the rare variant analyses based on statistical
models were proposed, including C-alpha (Neale et al., 2011), SKAT (Wu et al.,
2011), SKAT-O (Lee et al., 2014) and HMVD (Cheng et al., 2016). There have
also been several methods summarizing rare variant information within a region into
a single genetic score (e.g. Li and Leal, 2008; Madsen and Browning, 2009; Price
et al., 2010). However, the statistical powers of these set-based tests are still usually
insufficient. Also, another problem is the effect size estimation. Due to the extremely
low frequency of these variants, the ordinary estimators of effect measures (e.g., odds-
ratio) are quite unstable. Existing set-based inference frameworks only provided
testing methods, and there have been no effective methods to quantifying the effect
sizes of these variants.
In this article, we propose an efficient set-based inference framework that addresses
the two important issues simultaneously based on the Bayesian semiparametric mul-
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tilevel mixture models (e.g. Shen and Louis, 1999). We propose to use a multilevel
hierarchical model that incorporate the variations in set-specific effects and variant-
specific effects, and to apply the optimal discovery procedure (ODP) that achieves the
largest overall power in multiple significance testing (Storey, 2007; Noma and Matsui,
2012) via the empirical Bayes framework. As shown in Section 3, the ODP gains the
overall powers in the set-based test compared with existing methods such as SKAT-O
and HMVD. The multiplicity of the set-based ODP can be adequately adjusted with
controlling the false discovery rate (FDR; Benjamini and Hochberg, 1995; Storey,
2002). In addition, the Bayesian formulation enables accurate “set-based” effect size
estimation. It should be noted that the effect size estimation for individual SNPs
cannot be suitably implemented, even for the Bayesian shrinkage estimators because
unstable ordinary estimators (e.g., maximum likelihood estimator) for the extremely
low frequency variants are too shrunken and strongly biased. Thus, most of previous
rare variant analyses did not discuss the effect size estimates due to these substantial
limitations. However, using the proposed multilevel hierarchical model, we can ob-
tain accurate estimates of effect size distributions of individual units of the set-based
analysis alternatively via Bayesian optimal estimation of the empirical distribution
function (Shen and Louis, 1998). The set-based distribution estimate would provide
an additional new relevant information to the set-based inferences. After presenting
these proposed methods, we evaluate their performance by simulation studies and as-
sess their practical usefulness via application to the PennCATH study (Reilly et al.,
2011), a large GWAS for coronary artery disease (CAD).
This article is organized as follows. We describe the proposed model model and
the ODP in Section 2. In Section 3, we provide some simulation results, and we apply
our approach to the PennCATH study of CAD in Section 4. Lastly, we conclude with
some discussion in Section 5. Technical details are given in the Appendix.
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2 Methods
2.1 Hierarchical mixture modeling for effect sizes of multiple rare variants
Suppose we are interested in group associations of R regions and Mr rare variants are
included in the rth region (r = 1, . . . , R). Let Yrk denote a nrk-dimensional vector of
outcome for the kth variant in the rth region. If there are no missing values, nrk = n
and Yrk = Y . Correspondingly, let Xrk be a nrk × q matrix of baseline covariates,
and grk be a nrk-dimensional vector of number of minor alleles, so that the elements
of grk are 0, 1 or 2. We first consider the following generalized linear model:
ψ{E(Yrk)} = Xrkαrk + βrkgrk, k = 1, . . . ,Mr, r = 1, . . . , R, (1)
where αrk is a q-dimensional vector of regression coefficient and βrk is the (scalar)
effect size of the kth variant in the rth region. The primary concern in this article
is inference on the vector of true effect sizes in each region, βr = (βr1, . . . , βrMr)
t
for r = 1, . . . , R. When βr = 0, the rth region is not associated with the outcome.
On the other hand, the rth region is associated with the outcome when at least one
element in βr is non-zero. To express such a structure, we consider the following
mixture model for βr:
pi(βr) = pig0(βr) + (1− pi)g1(βr), (2)
where pi is the prior probability of being null, namely, pi = P (βr1 = 0, . . . , βrMr = 0),
and g0 and g1 are null and non-null distributions. It is reasonable to force g0(βr)
be the Mr-dimensional one-point distribution on 0. We propose estimating the non-
null distribution g1(·) in a nonparametric way by incorporating smooth-by-rouging
approach (Shen and Louis, 1999), that is, we approximate g1(·) by the following form:
g1(βr) =
Mr∏
k=1
L∑
`=1
p`δa`(βrk),
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where δc(x) denotes a one-point distribution on x = c, a1, . . . , aL are fixed knots
specified by the user and p1, . . . , pL are probabilities of βrk = a`, satisfying
∑L
`=1 p` =
1. The probabilities p`’s will be estimated later.
Combination of (1) and (2) gives the posterior distribution of β = (βt1, . . . , β
t
R)
t
given by
pipos(β; Θ) =
R∏
r=1
pi(βr; Θ)
Mr∏
k=1
∫
L(βrk, αrk|Yrk, Xrk)dαrk,
where L(βrk, αrk|Yrk, Xrk) is the likelihood function of (1), and Θ = (pi, p1, . . . , pL)t
is a vector of unknown parameters in (2). Since L(βrk, αrk|Yrk, Xrk) may have com-
plicated forms, the computation of the integral appeared in the above distribution
would be computationally intensive. Alternatively, we consider an approximated
method for computing the posterior distribution of β. Specifically, we approximate∫
L(βrk, αrk|Yrk, Xrk)dαrk as a function of βrk by a normal distribution with mean
and variance corresponding to the maximum likelihood estimate β̂rk and its asymp-
totic variance s2rk of βrk based on the model (1). The approximation is valid under
relatively large nrk, which would be often satisfied in practice. Therefore, the ap-
proximated posterior distribution of β is given by
piapos(β; Θ) =
R∏
r=1
pi(βr; Θ)
Mr∏
k=1
φ(β̂rk;βrk, s
2
rk). (3)
This approximated posterior distribution can be derived from the following multilevel
models:
β̂rk|βrk ∼ N(βrk, s2rk), k = 1, . . . ,Mr,
pi(βr) = pig0(βr) + (1− pi)g1(βr),
(4)
independently for r = 1, . . . , R. In what follows, we call the model (4) semiparametric
multilevel mixture model. Under the model (4), β̂1, . . . , β̂R are mutually independent
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and the marginal distribution of β̂r is given by
f(β̂r; Θ) = pi
Mr∏
k=1
φ(β̂rk; 0, s
2
rk) + (1− pi)
Mr∏
k=1
L∑
`=1
p`φ(β̂rk; a`, s
2
rk)
≡ pif0(β̂r) + (1− pi)f1(β̂r;P ),
where P = (p1, . . . , pL)
t is the mixing probabilities in g1(βr). The unknown model
parameters Θ = (pi, P t)t can be estimated by maximizing the marginal likelihood
function, the product of f(β̂r; Θ) for r = 1, . . . , R, and the maximization can be
efficiently carried out via EM-algorithm (Dempster and Rubin, 1977), where its details
are provided in the Appendix.
2.2 Region-specific and variant-specific indices
Some region-specific indices are useful for screening regions. Let zr be the indicator
variable for null/non-null status for the rth region, such that zr = 1 if the rth region
is non-null and zr otherwise. The value of zr is unknown and has the prior probability
P (zr = 1) = 1 − pi. Let D = {β̂rk, srk, k = 1, . . . ,Mr, r = 1, . . . , R}. The following
posterior probability of being non-null is useful for screening regions:
P (zk = 1|D; Θ) = (1− pi)f1(β̂r;P )
pif0(β̂) + (1− pi)f1(β̂r;P )
.
The effect sizes of each variant βrk can be estimated by the posterior mean given by
E[βrk|D; Θ] = P (zk = 1|D; Θ)
L∑
`=1
a`P (wrk = `|zk = 1, D; Θ),
where
P (wrk = `|zk = 1, D; Θ) = p`φ(β̂rk; a`, s
2
rk)∑L
`=1 p`φ(β̂rk; a`, s
2
rk)
≡ γrk`(Θ).
The distribution of effect sizes, βr1, . . . , βrMr in each region would provide more valu-
able and interpretable information than the point estimates. In this case, the his-
togram of posterior means is not necessarily a good estimator of the true distribution
(Shen and Louis, 1998), and the optimal estimator of the distribution function is
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given by
Hr(t;Θ) ≡ 1
Mr
Mr∑
k=1
P (βrk ≤ t|D; Θ)
= I(t ≥ 0)P (zr = 0|D; Θ) + P (zr = 1|D; Θ)
Mr
Mr∑
k=1
L∑
`=1
I(a` ≤ t)γrk`(Θ).
(5)
The posterior indices can be estimated by replacing Θ with Θ̂ in (5).
2.3 Screening regions based on the optimal discovery procedure
For detecting and ranking multiple group associations, we follow the optimal dis-
covery procedure (Storey, 2007; Storey et al., 2007) and select significant regions by
controlling false discovery rate. To this end, we use the following statistics for each
region induced from the estimated semiparametric multilevel mixture model:
ODPr =
f1(β̂r; P̂ )
f0(β̂r)
, r = 1, . . . , R. (6)
This is a model-based version of the optimal discovery statistic (Cao et al., 2009;
Noma and Matsui, 2012, 2013). For each r, we define an index set Ir in which ODP
statistics are equal or greater than ODPr. For Ir, we can evaluate the model-based
false discovery rate (e.g. McLachlan et al., 2006),
FDRr =
1
|Ir|
∑
j∈Ir
P (zr = 0|D; Θ̂),
We identify the optimal r whose FDRr is maximum and smaller than pre-specified
proportion of false discovery, e.g. 5%. Due to the flexibility of the semiparametric
modeling of the non-null distribution, the proposed method would adequately control
the false discovery rate in a wide range of underlying true structures of effect sizes.
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3 Simulation study
We assessed the performance of the proposed method through simulation studies. We
considered n = 2000 individuals, R = 500 regions. We randomly generated the num-
ber of variants Mr in each region from 1+[Γ(5, 1)], where Γ(a, b) denotes the Gamma
distribution and [·] is the round function. Then, M = ∑Rr=1Mr is the total number
of rare variants, which were around 3000 in simulations. The minor allele frequency
(MAF) of each variant was generated from the uniform distribution on [0.005, 0.01].
For generating genotype data, we first generated two M -dimensional binary vectors
a1 and a2 using rmvbin function in R with a correlation matrix R = (ρ
|i−j|)i,j=1,...,M
with ρ = 0.1. We then set the genotype vector (g11, . . . , g1M1 , g21, . . . , gRMR) to
a1 + a2. Also we generated two clinical covariates, X1 and X2 from the standard
normal distribution and the Bernoulli distribution with success probability 0.5. We
considered two cases of response variables and used the following generating model:
(continuous) Y = γ1X1 + γ2X2 +
R∑
r=1
Mr∑
k=1
βrkgrk + ε, ε ∼ N(0, 1)
(binary) Y ∼ Ber{eη/(1 + eη)}, η = γ1X1 + γ2X2 +
R∑
r=1
Mr∑
k=1
βrkgrk,
where γ1 = γ2 = 0.5. For the effect sizes of βr = (βr1, . . . , βrMr)
t in each region, we
randomly sampled from the following distribution:
pi(βr) = pig0(βr) + (1− pi)
Mr∏
k=1
g(βrk),
g(x) = 0.9φ(x; 0.5, (0.2)2) + 0.1φ(x;−0.3, (0.1)2),
where we considered two cases of null probability pi, pi = 0.5 and 0.7.
For the simulated dataset, we applied the proposed ODP method with knots
(a1, . . . , aL) = (−1.00,−0.99, . . . , 0.99, 1.00). As the alternative screening methods,
we applied the optimal sequential kernel association test (SKAT-O; Lee et al., 2014)
and the association test based on hidden Markov model (HMVD; Cheng et al., 2016)
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to each region to calculate p-value, both of which are available as R packages. Then,
significant regions are selected using the q-value method (Storey and Tibshirani, 2003)
with controlling the FDR. Based on 200 simulations, we calculated the average num-
ber of detected regions and true positives at FDR=5, 10, 15, or 20% for the two
types of responses, which are summarized in Table S1. Overall, larger numbers of
significant regions and true positives are discovered by the proposed method, which
indicate its efficiency, compared with the direct use of q-values combined with the ex-
isting methods. It is also confirmed that the efficiency gain of the proposed method
appeared for smaller values of pi and larger values of FDR.
Table 1: Average numbers of significant biomarkers and true positives for the pro-
posed and alternative methods based on 200 simulations.
# significant regions # true positive
FDR levels 5% 10% 15% 20% 5% 10% 15% 20%
Continuous (pi = 0.7)
ODP (proposed) 107.8 131.2 149.9 167.4 101.2 116.3 124.9 131.0
SKAT-O (q-value) 81.8 102.9 118.8 133.9 78.1 93.8 103.5 110.7
HMVD (q-value) 89.7 110.9 128.1 144.8 84.6 98.9 107.9 114.5
Continuous (pi = 0.5)
ODP (proposed) 166.2 214.4 251.6 285.0 155.7 188.8 208.7 221.9
SKAT-O (q-value) 106.8 146.0 176.9 205.6 102.2 134.2 155.6 172.2
HMVD (q-value) 122.8 162.7 193.6 222.1 116.5 146.7 166.0 180.8
Binary (pi = 0.7)
ODP (proposed) 27.5 50.5 72.0 93.2 26.6 46.9 63.4 77.5
SKAT-O (q-value) 16.0 30.3 44.6 59.4 15.3 27.8 39.1 49.5
HMVD (q-value) 24.9 43.4 59.4 75.6 23.5 38.9 50.5 60.7
Binary (pi = 0.5)
ODP (proposed) 53.6 109.5 161.5 211.1 51.6 99.6 138.0 168.5
SKAT-O (q-value) 17.9 41.1 65.1 89.2 17.3 38.6 58.7 77.4
qHMVD (q-value) 31.8 61.7 90.9 117.9 30.6 56.9 80.2 99.4
4 Application
To illustrate the proposed methods in practice, we analyzed a GWAS dataset from
the PennCATH study (Reilly et al., 2011). The PennCATH study is a hospital-based
cohort study to evaluate genetic risk factors and biomarkers for CAD, and a nested
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case-control GWAS study of angiographic CAD was conducted (Reilly et al., 2011).
After the same preprocessing with Reed et al. (2015), we involved data on 933 cases
and 468 controls (1401 individuals in total) for the GWAS analyses. For the rare
variant analyses, we selected the variants whose MAFs were smaller than 5% and
at least 3 individuals had the corresponding alleles. We defined the sets of analyses
by the groups of SNPs on the same protein coding genes. Then, we adopted genetic
regions who have at least 10 rare variants, which results in 1094 regions with total
24902 SNPs variants in the analyses.
We fitted the proposed multilevel model by the logistic regression model where the
outcome variable was the disease status (case = 1, control = 0), and four covariates,
age, sex (male = 1, female = 0), high- and low-density lipoprotein cholesterol are
involved as adjustment variables. Then, we applied the proposed multilevel mixture
model with the knots {−1.000,−0.995, . . . , 0.995, 1.000}. By the EM algorithm, the
estimated null-probability was pi = 0.861. The histogram of z-scores β̂rk/srk and
estimated non-null distribution are shown in Figure 2, which shows that almost all
the non-null variants have negative effect sizes. Also, a large fraction (about 70%) of
the non-null variants was indicated to have log OR smaller than −0.20 (for OR scale,
about 0.80). In addition, 4% of non-null variants were estimated to have log ORs
smaller than −0.50 (for OR scale, about 0.60), thus possibly have strong preventive
factors of CAD.
For the set-based testing analyses, we first applied SKAT-O and HMVD methods.
However, applying the q-value method for controlling FDR (Storey and Tibshirani,
2003), no significant regions were detected under FDR control at 5%. Even relaxing
the threshold to FDR at 20%, SKAT-O detected only 3 significant regions. On the
other hand, applying the proposed method, we could detect 74 regions under FDR
control at 5%. The number of significant sets was much greater than those of the
existing methods. The detailed descriptions of the detected regions were provided in
the Supplementary Materials.
In addition, using the Bayesian optimal distribution function estimator given by
(5), we estimated the effect size distributions for SNPs of each region. In Figure 2,
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we show the estimated distribution functions in four selected regions which corre-
sponds to ones having the largest upper 5% quantile, the smallest lower 5% quantile,
the largest and smallest standard deviations of the estimated distribution functions,
respectively. The estimated frequencies of the null component were different among
these regions, and these estimates indicated certain small proportions of SNPs might
have large preventive effects (log OR < −0.5) for CAD. Also, in the region OLFM3,
in spite of the large proportion of null variants, the proposed method could effectively
detect such region. Conventional SNP-specific ML and Bayes estimates cannot pro-
vide useful snapshots of these effect size information, so these distribution estimates
would provide useful summary for assessing the potential impacts of the detected
variants.
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Figure 1: Histgram of z scores of all the variants (left) and estimated distribution of
the non-null distribution of effect sizes (right).
5 Discussion
In this article, we developed effective set-based testing and estimating methods for
rare variant analyses. As show in the simulation studies of Section 3, we could show
the overall powers of the set-based tests were improved by the theoretically most
powerful testing method, ODP. In addition, using the multilevel hierarchical mixture
12
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Figure 2: The estimated region-wise distribution of effect sizes in selected four selected
regions. The bold line on the origin represents the distribution of null effects of rare
variants.
model, the empirical Bayes inference could borrow the strengths of the among- and
within-variants information. These advantages were also reflected to the effect size
estimation method, the Bayesian estimator of empirical distribution function of the
variant-specific effect sizes. Since one of the main purpose of the rare variant analyses
is screening of candidate SNPs for further investigations, the effect size information
would be relevant information for the prioritizing steps.
In the applications to PennCATH study, we could detect 74 significant regions un-
der FDR at 5%. The number of significant regions were much greater than those of the
common rare variant analysis procedures with SKAT-O and HMVD. The discordance
of these methods would reflect the relative performances of them in the simulation
studies in Section 3. Along with the existing evidence for the performances of ODP
(e.g. Storey, 2007; Matsui et al., 2018; Otani et al., 2018), the proposed method would
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have greater overall powers under practical situations.
Besides, the results of the effect size distribution estimation indicated there exists a
large number of variants with strong preventive effects of CAD. There have no effective
methods that provide effective summary of effect size information in rare variant
analyses, thus the proposed new framework would provide relevant information for
these studies. Also, although these results indicate the existence of a lot of preventive
factors of CAD, the existing methods (i.e., SKAT-O and HMVD) could not detect
these factors by the limitations of statistical powers. The proposed ODP also still has
the limitation of power, but the effect size estimates provide an alternative effective
information to the testing results how these rare variants potentially influences to the
heritability of diseases, behaviors, and other phenotypes. The power analyses using
this framework would be possible (Matsui and Noma, 2011). These new information
might provide effective hints for the missing heritability problem, and might derive
new insights via applying existing rare variant analyses. These practical investigations
are subjects for further researches.
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Appendix: EM algorithm for computing estimates of the model
parameters
By introducing latent variables zr and wrk, the multilevel model (4) can be expressed
as
β̂rk|zr = 0 ∼ N(0, s2rk), β̂rk|(zr = 1, wrk = `) ∼ N(a`, s2rk)
zr ∼ Ber(1− pi), P (wrk = `) = p`, ` = 1, . . . , L.
The complete log-likelihood given the latent variables zr’s and wrk’s is given by
logLc(Θ) =
R∑
r=1
(1− zr)
{
Mr∑
k=1
log φ(β̂rk; 0, s
2
rk) + log pi
}
+
R∑
r=1
zr
[
Mr∑
k=1
L∑
`=1
I(wrk = `)
{
log φ(β̂rk; a`, s
2
rk) + log p`
}
+ log(1− pi)
]
.
By taking the expectation with respect to the latent variables, we have the following
objective function in the M-step:
Q(Θ|Θ(t)) =
R∑
r=1
(1− ξ(t)r )
{
Mr∑
k=1
log φ(β̂rk; 0, s
2
rk) + log pi
}
+
R∑
r=1
ξ(t)r
[
Mr∑
k=1
L∑
`=1
γ
(t)
rk`
{
log φ(β̂rk; a`, s
2
rk) + log p`
}
+ log(1− pi)
]
,
where ξ
(t)
r = P (zr = 1|D; Θ(t)) and γ(t)rk` = P (wrk = `|zr = 1, D; Θ(t)). The maximiza-
tion steps of Q(Θ|Θ(t)) reduces to the updating steps given by
pi(t+1) =
1
R
R∑
r=1
(1− ξ(t)r ), p(t+1)` =
∑R
r=1
∑Mr
k=1 ξ
(t)
r γ
(t)
rk`∑R
r=1Mrξ
(t)
r
, ` = 1, . . . , L.
Hence, the EM algorithm requires computing ξ
(t)
r and γ
(t)
rk` in the E-step and update
pi and p`’s in the M-step until convergence.
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Table S1: List of 74 regions detected by the proposed optimal
discovery procedure with FDR= 5%, and summary statistics of
effect sizes of rare variants in each region, including the number of
rare variants (#RV), Q-value for the region, and mean, standard
deviation (sd) and five (5%, 25%, 50%, 75%, 95%) quantiles of
the distribution of effect sizes. The regions are arranged in the
ascending order of Q-values.
Gene #RV Q-value mean sd 5% 25% 50% 75% 95%
RALGAPA2 29 7.62×10−12 -0.292 0.142 -0.495 -0.385 -0.305 -0.215 -0.035
PKN2 16 5.40×10−9 -0.316 0.134 -0.525 -0.405 -0.320 -0.235 -0.090
LRRTM4 44 8.53×10−9 -0.266 0.158 -0.500 -0.370 -0.280 -0.175 0.025
ABCC4 33 1.94×10−8 -0.279 0.149 -0.500 -0.380 -0.290 -0.195 -0.010
MCTP1 28 4.61×10−8 -0.280 0.147 -0.495 -0.380 -0.290 -0.195 -0.015
RSU1 31 9.23×10−7 -0.270 0.154 -0.500 -0.370 -0.285 -0.185 0.015
MAN1A1 13 5.44×10−6 -0.301 0.133 -0.500 -0.390 -0.310 -0.220 -0.070
PTPRK 56 9.04×10−6 -0.269 0.151 -0.490 -0.370 -0.285 -0.185 0.005
DPP10 18 1.20×10−5 -0.279 0.150 -0.500 -0.385 -0.295 -0.195 0.000
C1orf21 15 1.90×10−5 -0.258 0.179 -0.505 -0.380 -0.290 -0.165 0.100
MKL2 19 2.68×10−5 -0.271 0.149 -0.495 -0.370 -0.285 -0.185 0.000
DIAPH3 18 3.56×10−5 -0.275 0.135 -0.480 -0.365 -0.285 -0.199 -0.035
GAS7 20 4.76×10−5 -0.278 0.151 -0.505 -0.380 -0.290 -0.190 -0.005
EPB41L4B 14 6.05×10−5 -0.276 0.153 -0.500 -0.380 -0.290 -0.190 0.005
SLC24A3 61 8.08×10−5 -0.259 0.153 -0.480 -0.360 -0.275 -0.175 0.025
UTRN 46 1.04×10−4 -0.268 0.152 -0.495 -0.370 -0.280 -0.185 0.010
EPHB2 20 1.44×10−4 -0.285 0.148 -0.510 -0.380 -0.295 -0.200 -0.025
VAV2 16 1.89×10−4 -0.282 0.148 -0.505 -0.385 -0.295 -0.200 -0.020
CYB5R4 11 2.42×10−4 -0.292 0.130 -0.490 -0.380 -0.300 -0.215 -0.065
PRKCH 46 2.96×10−4 -0.263 0.147 -0.485 -0.360 -0.275 -0.175 0.000
SYN3 40 3.48×10−4 -0.255 0.159 -0.490 -0.365 -0.270 -0.165 0.040
CACNB2 32 4.01×10−4 -0.267 0.154 -0.495 -0.370 -0.280 -0.180 0.015
1
Gene #RV Q-value mean sd 5% 25% 50% 75% 95%
NTRK2 30 4.67×10−4 -0.241 0.168 -0.475 -0.360 -0.260 -0.150 0.085
CGNL1 19 5.34×10−4 -0.275 0.143 -0.490 -0.375 -0.285 -0.195 -0.020
CEP85L 11 6.01×10−4 -0.285 0.140 -0.495 -0.380 -0.295 -0.200 -0.040
KLHL1 26 6.78×10−4 -0.265 0.143 -0.475 -0.360 -0.275 -0.185 -0.005
ZNRF3 18 7.58×10−4 -0.277 0.145 -0.495 -0.375 -0.285 -0.190 -0.020
CAMKMT 16 8.45×10−4 -0.292 0.143 -0.510 -0.385 -0.300 -0.210 -0.040
GRIK4 30 9.27×10−4 -0.276 0.144 -0.490 -0.370 -0.290 -0.190 -0.015
ANO3 18 1.03×10−3 -0.272 0.140 -0.480 -0.365 -0.280 -0.190 -0.030
LINGO2 67 1.14×10−3 -0.245 0.159 -0.475 -0.355 -0.265 -0.160 0.060
INTS7 14 1.28×10−3 -0.269 0.152 -0.495 -0.370 -0.285 -0.180 0.010
PRKD1 18 1.43×10−3 -0.269 0.149 -0.485 -0.370 -0.280 -0.185 0.005
PHACTR1 51 1.58×10−3 -0.259 0.143 -0.470 -0.355 -0.270 -0.180 0.005
RBM47 14 1.78×10−3 -0.256 0.167 -0.495 -0.370 -0.270 -0.160 0.055
CNTLN 22 1.99×10−3 -0.274 0.147 -0.495 -0.370 -0.285 -0.190 -0.015
ZNF618 14 2.32×10−3 -0.269 0.151 -0.490 -0.370 -0.285 -0.185 0.010
ITFG1 12 2.73×10−3 -0.273 0.128 -0.465 -0.360 -0.280 -0.195 -0.055
PIP4K2A 11 3.30×10−3 -0.272 0.134 -0.475 -0.365 -0.280 -0.195 -0.040
RGL1 21 3.86×10−3 -0.261 0.136 -0.465 -0.355 -0.270 -0.180 -0.020
CCDC146 19 4.58×10−3 -0.265 0.158 -0.490 -0.370 -0.285 -0.185 0.040
DIP2C 31 5.46×10−3 -0.236 0.162 -0.475 -0.345 -0.250 -0.145 0.065
PID1 18 6.38×10−3 -0.260 0.165 -0.495 -0.370 -0.275 -0.175 0.060
NR6A1 14 7.30×10−3 -0.285 0.144 -0.500 -0.380 -0.295 -0.200 -0.030
UNC5C 37 8.25×10−3 -0.253 0.154 -0.480 -0.355 -0.265 -0.165 0.035
PTGFRN 21 9.24×10−3 -0.262 0.138 -0.465 -0.355 -0.275 -0.180 -0.015
RAPGEF4 24 1.02×10−2 -0.264 0.150 -0.490 -0.365 -0.275 -0.180 0.010
NREP 12 1.13×10−2 -0.275 0.152 -0.500 -0.375 -0.290 -0.190 0.000
IGF1R 31 1.24×10−2 -0.256 0.150 -0.475 -0.355 -0.270 -0.175 0.025
MYCBP2 12 1.35×10−2 -0.263 0.151 -0.485 -0.365 -0.280 -0.180 0.020
NR3C2 18 1.48×10−2 -0.270 0.149 -0.495 -0.370 -0.285 -0.190 0.000
BCAS3 30 1.62×10−2 -0.265 0.152 -0.490 -0.370 -0.280 -0.180 0.010
CACNA2D3 45 1.75×10−2 -0.257 0.151 -0.480 -0.355 -0.270 -0.175 0.020
TSHZ2 16 1.89×10−2 -0.261 0.158 -0.495 -0.365 -0.275 -0.170 0.035
MSR1 17 2.02×10−2 -0.263 0.143 -0.475 -0.360 -0.275 -0.185 -0.005
ICA1 22 2.16×10−2 -0.254 0.155 -0.480 -0.360 -0.270 -0.170 0.040
ADAMTS17 43 2.29×10−2 -0.247 0.160 -0.480 -0.355 -0.265 -0.155 0.050
2
Gene #RV Q-value mean sd 5% 25% 50% 75% 95%
KCNQ5 41 2.43×10−2 -0.253 0.149 -0.470 -0.350 -0.265 -0.170 0.020
VAV3 16 2.55×10−2 -0.258 0.152 -0.485 -0.360 -0.270 -0.170 0.020
HECTD4 12 2.69×10−2 -0.291 0.145 -0.510 -0.385 -0.300 -0.210 -0.030
VPS13D 11 2.83×10−2 -0.257 0.155 -0.475 -0.360 -0.275 -0.180 0.040
LDLRAD3 29 2.99×10−2 -0.254 0.153 -0.480 -0.355 -0.270 -0.170 0.025
UVRAG 23 3.15×10−2 -0.263 0.140 -0.475 -0.355 -0.270 -0.180 -0.015
MPPED2 10 3.31×10−2 -0.276 0.141 -0.485 -0.370 -0.290 -0.195 -0.025
CREBBP 20 3.47×10−2 -0.268 0.141 -0.475 -0.360 -0.280 -0.185 -0.020
NTM 11 3.62×10−2 -0.268 0.136 -0.470 -0.360 -0.275 -0.190 -0.025
MAN1C1 12 3.78×10−2 -0.277 0.149 -0.495 -0.380 -0.290 -0.190 -0.010
ARHGAP22 13 3.95×10−2 -0.274 0.143 -0.490 -0.370 -0.285 -0.195 -0.015
SMARCA2 18 4.12×10−2 -0.264 0.145 -0.480 -0.360 -0.275 -0.180 -0.005
RRP15 10 4.29×10−2 -0.268 0.137 -0.475 -0.355 -0.280 -0.190 -0.025
MAMDC2 11 4.45×10−2 -0.277 0.149 -0.500 -0.380 -0.285 -0.190 -0.010
GCOM1 17 4.63×10−2 -0.268 0.145 -0.485 -0.365 -0.280 -0.185 -0.005
JPH1 15 4.81×10−2 -0.267 0.143 -0.480 -0.360 -0.280 -0.185 -0.010
LY75-CD302 11 5.00×10−2 -0.263 0.144 -0.475 -0.360 -0.275 -0.180 0.000
3
